AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02705560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy based drink
Description: 600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
Study NCT02819206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Detection of bacteria will be performed on a blood sample
Study NCT03845569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein intake reduction
Description: Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
Study NCT03845569 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Three day Controlled Diet
Description: Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
Study NCT01685164 — intervention group
Intervention type: OTHER
Intervention: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
Description: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
Study NCT02520284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab 150 mg administered via SC injection
Study NCT02520284 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Andecaliximab
Description: Andecaliximab 150 mg administered via SC injection
Study NCT02520284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to andecaliximab administered via SC injection
Study NCT02520284 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to andecaliximab administered via SC injection
Study NCT03268122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Contact Isolation
Description: With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
Study NCT03268122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Contact Isolation
Description: With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia.
Study NCT02790268 — intervention group
Intervention type: PROCEDURE
Intervention: Lens Subluxation Surgery
Description: Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
Study NCT01477320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40 mg IV daily and tube feed.
Description: Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily.
Study NCT01477320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and tube feed
Description: Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo.
Study NCT02968732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Study NCT04597528 — intervention group
Intervention type: OTHER
Intervention: Elective Induction
Description: All patients admitted to the labour room would be approached to be enrolled in the study.~Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored.~The data would later be abstracted to an excel sheet.
Study NCT02331251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02331251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02331251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02331251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT02331251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT02331251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02331251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Study NCT01251250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01251250 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study NCT01251250 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT01251250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01251250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01251250 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study NCT01251250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: azadirachta indica
Description: Given orally
Study NCT01251250 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT01907360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 (methylphenidate hydrochloride)
Study NCT03583177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT03747198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: methylsulfonylmethane
Description: Subjects will be given 2 g/day methylsulfonylmethane.
Study NCT03747198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given 2 g/day placebo (rice flour).
Study NCT03090230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relay Pro Thoracic Stent-Graft System
Description: RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
Study NCT03322748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual physical therapy+ strengthening of lower limbs muscles
Description: Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
Study NCT03322748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual physical therapy
Description: Usual physical therapy
Study NCT01848951 — intervention group
Intervention type: DRUG
Intervention: Epidural
Description: The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
Study NCT01848951 — intervention group
Intervention type: DRUG
Intervention: TAP Block
Description: The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
Study NCT04983641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Visit Messages
Description: Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits
Study NCT01744223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 1
Description: Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
Study NCT01744223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
Study NCT01744223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 2
Description: Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
Study NCT01744223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 3
Description: Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
Study NCT01744223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 4
Description: Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
Study NCT01744223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCT
Description: all subjects will receive an alpha beta depleted donor transplant as part of treatment
Study NCT01777269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride plus tamsulosin
Description: Take 1 capsule daily
Study NCT01777269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one capsule daily
Study NCT04309344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEREWOLF COBLATION System
Description: The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
Study NCT04309344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: mechanical debridement
Study NCT03120767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk and Resilience
Description: The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills.
Study NCT03120767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk and Resilience
Description: The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills.
Study NCT03120767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Wellness Programming
Description: During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester.
Study NCT01775267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Associating liver partition and portal vein ligation for staged hepatectomy
Study NCT01775267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal vein embolization or ligation
Study NCT02636179 — intervention group
Intervention type: OTHER
Intervention: Comparative epidemiological survey
Description: The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
Study NCT01084655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Study NCT02918578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone group
Description: Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling.
Study NCT02918578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone and SMS group
Description: The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months.
Study NCT02918578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single writing group
Description: The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone.
Study NCT02652403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete conventional dentures
Description: The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments.
Study NCT02652403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete simplified dentures
Description: For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
Study NCT00569595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Stimulating Disease Prevention Program
Description: The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
Study NCT00569595 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fighting Cancer with Advice
Description: Patient health counseling program by lay health educators entitled Fighting Cancer with Advice.
Study NCT02796560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand name travoprost
Description: Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
Study NCT02796560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic travoprost
Description: Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
Study NCT00596778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chest physiotherapy
Description: The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
Study NCT01414374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal medicine
Description: Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
Study NCT01414374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
Study NCT03905161 — intervention group
Intervention type: OTHER
Intervention: 6-minute walk test
Description: The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
Study NCT02037971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
Study NCT02037971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
Study NCT04589429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine 10 MG/ML
Description: intrathecal morphine 300 micrograms
Study NCT01622166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychodynamic art therapy
Description: 2 sessions à 1.5 hrs /week, intervention duration 6 weeks
Study NCT03399019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: initial loading dose (0.5 \~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)
Study NCT03399019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: continuous infusion (0.75-3mg/kg/hr)
Study NCT03399019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1\~2 minutes
Study NCT04589429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10 MG/ML
Description: intrathecal morphine 300 micrograms
Study NCT04589429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine Hydrochloride 10 MG/ML
Description: intrathecal nalbuphine 2mg.
Study NCT00494481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib (ZD6474)
Description: once daily oral dose
Study NCT00494481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion
Study NCT00494481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study NCT01030198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RevLite (Laser Treatment)
Study NCT00637923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
Study NCT00637923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
Study NCT00637923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: One weekly injection of 180µg of peginterferon α-2a for 48 weeks.